Alcon Inc. (ACL) Tops Q2 EPS View By 14c; Guides FY08 Higher Than Expectations
More News related to ACL
- A Company and Industry Analysis of the European Pharmaceutical Sectors Providing the Latest Data on the Current Environment & Market Trends
- Alcon Announces Third Quarter 2008 Financial Release and Conference Call Dates
- Alcon Plans to Expand Manufacturing Facility in West Virginia
- Alcon Launches New AcrySof(R) ReSTOR(R) Intraocular Lens for Presbyopia Outside the U.S.
- Alcon Expands Refractive Surgery Options with the Introduction of the AcrySof(R) Phakic Intraocular Lens Outside the U.S.
More News related to Earnings
- WSI Industries (WSCI) Reports Q4 Earnings
- Alcoa (AA) Reports Q3 Adj-EPS of $0.37; Suspends Share Buyback
- Team (TISI) Reports In-Line Q1 Earnings
- Yum! Brands (YUM) Tops Q3 Earnings Views; Reaffirms Forecast
- CalAmp (CAMP) Reports Mixed Q2 Earnings; Guides Q3
Alcon Inc. (NYSE: ACL) reports Q2 EPS of $1.88, 14 cents better than the analyst estimate of $1.74. Revenues for the quarter were $1.74 billion, versus the consensus of $1.68 billion.
Sees FY08 EPS $6.48 to $6.54 versus consensus of $6.44.
Alcon, Inc. engages in the development, manufacture, and marketing of pharmaceuticals, surgical equipment and devices, and consumer eye care products to treat eye diseases and disorders.
Sign up at EasyStockAlerts.com To Be Alerted To Your Stock News Today!
Related Categories
EarningsGuidance
Hot List
Stocks Mentioned
+3.34Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
